PIDD-PCCR Cancer-related Drug Discovery RFA

Funding Opportunity Number

PIDD-PCCR-FY2021-01

Funding Opportunity Title

PIDD-PCCR Cancer-related Drug Discovery RFA

Key Dates

Events Cycle 1
Announcement

March 1, 2021

Due

April 12, 2021

Award Amount

Up to $50,000

Administrative Contact

John Fry ( johnfry@purdue.edu) or Karson Putt (puttk@purdue.edu)

Introduction and Background

To increase the prominence of cancer-releated research and drug discovery/development activities within Purdue University, the Purdue Institute for Drug Discovery (PIDD) and Purdue Center for Cancer Research (PCCR) are allocating funds to support research projects and/or the establishment of collaborative teams. 

Through decades of cancer research, our understanding of carcinogenesis has increased, progress towards cancer prevention has made great strides, and efficacious treatment options for some types of cancer have been developed. Yet even with this progress, a diagnosis of cancer still results in poor outcomes for the vast majority of patients. Therefore, a clear need exists to better understand the biological underpinnings of carcinogenesis in order to i) identify new targets for diagnostic and pharmaceutical intervention, ii) develop new therapeutics, and iii) translate these drugs into animal and human clinical trials.    

Examples of research directions responsive to this RFA include (but are not limited to):

  • Identification or structural characterization of new cellular cancer-related targets that would serve as good drug targets
  • Development of innovative immuno-oncology therapies
  • New diagnostic technology
  • Development of novel therapeutic lead
  • Translation of therapeutics into animal models, especially canine
  • Preclinical testing of existing therapeutic leads (PK, ADME/tox, etc.)

Ultimately, a successful project or team should raise the prominence of Purdue in its efforts to combat cancer, impact patient care by enabling the successful translation of laboratory discoveries into the clinic, provide a benefit to affiliated researchers, and/or lead to the attainment of external funding (e.g. R01s, multi-PI grants, center grants, etc.). We are especially interested in proposals that support or bring together diverse and new research teams that have the potential to generate new intellectual property, patents, and, potentially, companies. Projects that utilize the Center for Cancer Research shared resources or PIDD core facilities are also highly desired.

Applicants are encouraged to consult with the PCCR and/or PIDD leadership teams.  Questions or requests for consultations can be directed to either John Fry (johnfry@purdue.edu) or Karson Putt (puttk@purdue.edu).

General Guidelines:

  1. Qualification – Lead PI must currently be or become a member of PIDD or PCCR. Co-PIs or other key personnel are not required to be members, but membership is strongly encouraged. Only one application per PCCR or PIDD member is allowed; no exceptions.
  2. Proposal Length – Proposal should be single-spaced and a maximum of 3 pages in length (Calibri or similar font at 11pt) with no less than 0.5 inch page margins. References are not part of the page limit.
  3. Timeline – Funding will be available for 1 year.
  4. File format – Only .doc, .docx, or .pdf files will be accepted. Any figures should be embedded in the document and must fit within the maximum page limit.
  5. Progress Report and Future Reporting – Any funding and/or publications that are generated from this activity must be reported to the Institutes (John Fry, johnfry@purdue.edu, or Karson Putt, puttk@purdue.edu).
  6. Deadline – Applications must be received by 5:00 pm on Friday, April 12th, 2021. Applicants do not need to work with pre-award/SPS to submit an application for this internal RFA.  Applications should be submitted as a single document to the following PCCR online submission site:  https://purdue0.sharepoint.com/sites/PCCRGrants
  7. The award is contingent upon obtaining all of the necessary regulatory approvals (e.g., IRB, IACUC, PACUC) or a Memorandum of Understanding (MOU) pertaining to the work that has pending approvals.
  8. No cost extensions are highly discouraged. An exception might be considered on a case-by-case basis. Requests must be made to the administration of both PIDD and PCCR.

Award:

Up to $50,000 will be made available to the project.  Project duration should not exceed 1 year in total.  Budgets should adequately reflect the needs of the project.

Funds can be used for S&E, core facilities, and/or to support graduate student(s), post-doctoral student(s) and/or technical staff.  Travel, if deemed critical for the successful implementation of the program by the reviewers is allowable in the budget.

Funds cannot be used for faculty salaries, hospitality expenses, and F&A. If justified, equipment less than $2,500 is allowed.

Application Format:

The following information must be included within the maximum 3 page limit

  1. Project Title
  2. Overview of proposed project
  3. Specific aim(s)
    • Including milestones, quantitative project deliverables and/or metrics for success
  4. Significance
    • How will the research address unmet needs
    • How will the project help translate lab discoveries into positive clinical outcomes for patients or otherwise impact human health
  5. Approach
    • How will the project deliverables be met?
    • How will the resources be leveraged?
  6. Extramural funding strategy
    • Provide an outline of steps that will be taken to procure external funding after PIDD/PCCR support ends. This section should clearly describe how completion of milestones would aid in strengthening a planned or pending submission. Potential categories of extramural funding (e.g. philanthropic, government, corporate partnership), as well as specific sponsors or funding mechanisms within each category, should be indicated.
  7. List of additional resources in addition to funding required from the PCCR/PIDD to successfully implement the project (if applicable)

Additional information that must be included (not included in the page limit requirements)

  1. References
  2. List of key personnel/Co-PIs (in the case of pre-existing collaborations, personnel such as graduate students, post-docs or staff that are already collaborating may be listed as well)
  3. Budget justification
  4. NIH Biosketches for all involved PIs and key personnel

Review Criteria:

  1. Potential for the proposed project raising the prominence of Purdue, the PCCR and PIDD
  2. Scientific merit
  3. Potential for subsequent external follow-on funding (Center grants, multi-PI grants, R01s, etc.)
  4. Appropriateness of budget requested
  5. Feasibility of completing the proposed milestones within the proposed timeframe
  6. Potential impact on patient care via feasibility of translating academic discoveries into the clinic
  7. Synergy of collaborating faculty/co-personnel

 

Publications resulting from PIDD and PCCR support should be acknowledged as follows:

“The authors gratefully acknowledge support from the Purdue University Institute for Drug Discovery and and support from the Purdue University Center for Cancer Research, P30CA023168”

Announcement History and Updates

Funding Opportunity Number Summary of Change
PIDD-PCCR-FY2021-01 Initiation of Announcement